In the future, targeting HOX expression through Menin-MLL inhibition could thus potentially add to other non-chemotherapic agents, such as dactinomycin or venetoclax, which have recently shown promising anti-leukemic activity in distinct subgroups of NPM1-mutated AML patients [125,126,127]. The gene discussed is NPM1; the disease is acute myeloid leukemia.